资源描述:
《[英文原版 乳腺 外科] Subject Index.pdf》由会员上传分享,免费在线阅读,更多相关内容在行业资料-天天文库。
1、SubjectIndexNote:Pagenumbersfollowedby‘f’denotesfigures;‘t’denotestables;‘b’denotesboxes.AAlcohol,breastcancerrisks,108Abscess,seeBreastabscessALND,seeAxillarylymphnodedissectionAccessorymammarygland,3Alopecia,chemotherapysideeffect,263–264Accessoryn
2、ipple,3Amazia,3Acquiredamastia,3AnastrozoleAdenoidcysticcarcinoma,histology,128adjuvanttherapy,274–275,274t,276Adjuvantchemotherapyneoadjuvanttherapy,281tAdjuvantOnline.com,253–257,254fAnatomybenefits,250,250tadultbreast,3–13,5f,6f,7fconsensusgroupre
3、commendationsaxilla,12–13,12f,13f,14tGallenInternationalConsensusPanel,252,253t,fascia,9254blymphaticanatomy,12,12fNationalComprehensiveCancerNetwork,252,muscularanatomyofchestwall,6–9,7t,8f252b,253fneuralanatomy,9–11,10fNationalInstitutesofHealthCon
4、sensusPanel,252vascularanatomy,11–12,11fDNAmicroarrayanalysisinevaluation,255,255f,Anastrazole,ductalcarcinomainsitumanagement,256152historicalperspective,248Angiosarcoma,breast,338–339malebreastcancer,325b,328Apocrinecarcinoma,histology,128OncoTypeD
5、Xassay,256Areola,reconstruction,221–226,224fpatientselection,251–257,251bAromataseinhibitors,seealsoAnastrozole:Exemestane:principles,248–249,248bLetrozoleprospects,265–266adjuvanttherapy,274t,276regimensbreastcancerchemoprevention,116agents,258tneoa
6、djuvanttherapy,281tathracyclines,257–259toxicity,275combinations,259bAspirin,breastcancerchemoprevention,113dose-densechemotherapy,262Ataxiatelangiectasia,breastcancerassociation,105herceptin,260–262,261b,261fATM,breastcancermutations,105high-doseche
7、motherapywithautologousstemcellAxillasupport,262anatomy,12–13,12fschedules,263blymphnodes,13,13f,14ttaxanes,259–260muscles,8sideeffectsAxillarylymphnodedissection(ALND)long-termcomplicationscardiactoxicity,265cording,203cognition,264lymphedemaleukemi
8、a,265management,204–205ovarianfailure,264–265overview,203–207short-termprevention,204,204b,205–206alopecia,263–264riskfactors,203bfatigue,264staging,205tmyelosuppression,264symptoms,205bnauseaandvomiting,263–264treatment,206–207neurotoxicity,264major